We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GlaxoSmithKline’s Lung Therapy Fails to Meet COPD Survival Goal
GlaxoSmithKline’s Lung Therapy Fails to Meet COPD Survival Goal
GlaxoSmithKline’s Breo Ellipta failed to meet its primary goal in a pivotal clinical trial of curbing death risk in patients suffering from chronic pulmonary obstructive disease.